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Introduction: Despite recent modifications, the clinical definition of the acute respiratory distress syndrome (ARDS)
remains non-specific, leading to under-diagnosis and under-treatment. This study was designed to test the hypothesis
that a biomarker panel would be useful for biologic confirmation of the clinical diagnosis of ARDS in patients at risk of
developing ARDS due to severe sepsis.
Methods: This was a retrospective case control study of 100 patients with severe sepsis and no evidence of ARDS
compared to 100 patients with severe sepsis and evidence of ARDS on at least two of their first four ICU days. A panel
that included 11 biomarkers of inflammation, fibroblast activation, proteolytic injury, endothelial injury, and lung
epithelial injury was measured in plasma from the morning of ICU day two. A backward elimination model building
strategy on 1,000 bootstrapped data was used to select the best performing biomarkers for further consideration in a
logistic regression model for diagnosis of ARDS.
Results: Using the five best-performing biomarkers (surfactant protein-D (SP-D), receptor for advanced glycation
end-products (RAGE), interleukin-8 (IL-8), club cell secretory protein (CC-16), and interleukin-6 (IL-6)) the area under
the receiver operator characteristic curve (AUC) was 0.75 (95% CI: 0.7 to 0.84) for the diagnosis of ARDS. The AUC
improved to 0.82 (95% CI: 0.77 to 0.90) for diagnosis of severe ARDS, defined as ARDS present on all four of the
first four ICU days.
Conclusions: Abnormal levels of five plasma biomarkers including three biomarkers generated by lung epithelium
(SP-D, RAGE, CC-16) provided excellent discrimination for diagnosis of ARDS in patients with severe sepsis. Altered
levels of plasma biomarkers may be useful biologic confirmation of the diagnosis of ARDS in patients with sepsis,
and also potentially for selecting patients for clinical trials that are designed to reduce lung epithelial injury.Introduction
The Acute Respiratory Distress Syndrome (ARDS) is a
common clinical syndrome of acute lung inflammation,
non-cardiogenic pulmonary edema and acute respira-
tory failure [1]. Despite recent modifications [2] to the
American European Consensus Conference (AECC)
definition [3], the clinical definition of ARDS remains* Correspondence: lorraine.ware@vanderbilt.edu
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reproduction in any medium, provided the ornon-specific and is not uniformly applied. As a result,
ARDS remains underdiagnosed and undertreated.
The discovery and validation of biomarkers of myocar-
dial injury and ventricular overload such as troponin
and brain-natriuretic peptide (BNP) has transformed the
diagnosis, management and design of clinical trials in
conditions such as myocardial infarction and congestive
heart failure. In a similar way, identification of plasma
biomarkers that facilitate diagnosis of ARDS could improve
clinical care, enhance our understanding of pathophysi-
ology, and could be used to enroll a more homogeneous
group of patients into clinical trials of new therapies,
increasing the likelihood of detecting a treatment effect.
Although several plasma biomarkers have been studied intd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sis, rather than diagnosis. In addition, given the complex
pathophysiology of ARDS [5], it is unlikely that a single
biomarker will have adequate specificity for ARDS. Indeed,
several recent studies in ARDS have shown the superiority
of a multiple biomarker approach for diagnosis in patients
with trauma [6] and for prognosis in established ARDS
due to a variety of causes [7,8]. Several plasma biomarkers
have been studied in patients with ARDS, but no studies
have tested the possible value of a panel of plasma bio-
markers in patients with severe sepsis who have developed
ARDS by clinical criteria and determined if a combination
of abnormal biomarkers could be used for confirming the
diagnosis of ARDS on biologic grounds.
The current study was designed to test the hypothesis
that a biomarker panel would be useful for biologic con-
firmation of the clinical diagnosis of ARDS in patients at
risk of developing ARDS due to severe sepsis. We also
determined whether biomarkers that performed well for
diagnosis of ARDS in patients with severe trauma have
value in severe sepsis, an important consideration since
biomarker levels have been shown to differ substantially
between traumatic and non-traumatic ARDS [9].
Materials and methods
Study design and patient selection
This study is a retrospective nested case control study
within the Validating Acute Lung Injury bIomarkers for
Diagnosis (VALID) study. VALID is a 2,500 patient pro-
spective cohort study that has been enrolling critically ill
patients in the Vanderbilt Medical, Surgical, Trauma and
Cardiovascular ICUs since 2006 [10-12]. Patients are en-
rolled on the morning of ICU day 2 if they are not being
transferred out of the ICU. At the time of enrollment,
plasma is obtained for biomarker measurement. Compre-
hensive clinical data are collected for the first four ICU days
including severity of illness scoring (Simplified Acute
Physiology Score II (SAPS II) [13], Acute Physiology and
Chronic Health Evaluation II (APACHE II) [14]), daily
laboratory values, hemodynamics, ventilator settings, medi-
cations and daily phenotyping for severe sepsis, ARDS and
other organ failures. Thereafter, comprehensive clinical out-
comes are collected including duration of mechanical venti-
lation, length of ICU and hospital stay, hospital mortality
and long term mortality. The VALID study is approved by
the Vanderbilt Institutional Review Board. Informed con-
sent is obtained from patients or their surrogates; if patients
are unable to consent and no surrogates can be identified
then the Institutional Review Board has granted a waiver of
informed consent for this minimal risk study.
For the current case control study, 100 patients with se-
vere sepsis and no evidence of ARDS (defined as not meet-
ing AECC acute lung injury (ALI) or ARDS criteria) during
the first four ICU days serve as controls and 100 patientswith severe sepsis and evidence of ARDS (defined as meet-
ing AECC ALI or ARDS criteria) on at least two of the first
four ICU days serve as cases. For some analyses, cases were
further restricted to patients who had ARDS at the time of
blood draw on the morning of ICU day 2 (n = 91 pairs) or
to the most severely ill patients who met ARDS criteria on
all four days (n = 66 pairs). To minimize confounding of
biomarker associations with ARDS by clinical variables,
such as severity of illness, cases and controls were one-to-
one matched for severity of illness (APACHE II, within one
point), age (within 10 years), gender (one-to-one match)
and number of non-pulmonary organ failures (within one).
Definitions of severe sepsis and ARDS
For inclusion as a case or control, patients were required
to have severe sepsis at enrollment as defined by consensus
definitions [15]. The presence or absence of ARDS was de-
termined daily by review of all chest radiographs and blood
gases in the past 24 hours using criteria set forth by the
AECC [3]. When no blood gases were available the SpO2/
FiO2 ratio was utilized [16]. All chest radiographs were
reviewed by consensus of two trained physician investiga-
tors. When patients met chest radiograph and oxygenation
criteria for ARDS, then the medical record was thoroughly
reviewed for any evidence of a primary cardiogenic cause
of pulmonary edema [17]; patients with cardiogenic pul-
monary edema were excluded.
Biomarker selection and assays
Because there are very few prior studies of biomarkers for
diagnosis of ARDS, we selected a panel of biomarkers that
included top performing biomarkers from our recent study
in trauma-associated ARDS [6] (receptor for advanced
glycation end products (RAGE), procollagen peptide III
(PCPIII), BNP, angiopoietin-2 (ANG2) and IL-8) as well as
other biomarkers of lung epithelial injury and inflam-
mation (surfactant protein D (SPD), club cell secretory
protein (CC16, formerly known as Clara cell secretory
protein) and IL-6), and biomarkers that have been
associated with other lung diseases (matrix metallopro-
teases (MMP)-1, -3 and -9) [18-20]. All biomarkers were
assayed in duplicate in thawed plasma that was collected at
VALID enrollment using commercially available singleplex
ELISAs (RAGE and ANG2, R&D Systems Minneapolis,
MN, USA; SP-D, Yamasa Corporation, Tokyo, Japan;
CC16, BioVendor, Candler, NC, USA; BNP, Peninsula
Laboratories, San Carlos, CA, USA), multiplex ELISAs
(IL-6, IL-8, MMP-1, MMP-3, MMP-9, Meso Scale Dis-
covery, Rockville, MD, USA) or radioimmunoassay
(PCPIII, Peninsula Laboratories, San Carlos, CA, USA).
Statistical analysis
Demographic and clinical variables were assessed using
Wilcoxon signed rank tests for continuous variables and
Table 1 Demographic and clinical characteristics of 100
severe sepsis patients with ARDS (cases) and 100 severe






Age 56 (51, 65) 59 (51, 65) 0.97
Male 52 (52%) 52 (52%) 1.0
Caucasian 89 (89%) 79 (79%) 0.10
Current smoker 35 (35%) 40 (40%) 0.56
APACHE II 28 (24, 32) 28 (24, 32) 1.0
Source of ICU admit
Emergency room 27 (27%) 37 (37%) 0.027
Hospital floor 40 (40%) 21 (21%)
Other hospital 23 (23%) 22 (22%)
Operating room 9 (9%) 17 (17%)
Other 1 (1%) 3 (3%)
Day of ALI onset
ICU day 1 91 (91%) NA
ICU day 2 9 (9%)
Mechanical ventilationa 83 (83%) 58 (58%) <0.001
Any ventilatory supportb 89 (89%) 59 (59%) <0.001
Non-pulmonary organ failure
at enrollment
92 (92%) 91 (91%) 1.0
Vasopressors at enrollment 44 (44%) 43 (43%) 0.50
ICU stay (days) 9 (5, 13) 5 (3, 11) 0.003
Ventilator-free days 18 (2, 24) 25 (7, 28) <0.001
Hospital mortality 29 (29%) 27 (27%) 0.87
Data as median (1st and 3rd quartiles) or Number (%) as indicated. NA = not
applicable. aMechanical ventilation on any study day; bmechanical ventilation
or noninvasive ventilation on any study day. ALI, acute lung injury; APACHE II,
Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory
distress syndrome.
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pairing of the cases and controls. Biomarker values under-
went logarithmic transformation to reduce right skewness.
Values below the detection limit were imputed at half the
lower limit of detection for each biomarker. We used a
backward elimination model-building strategy on 1,000
bootstrapped data to select the biomarkers for further
consideration in the logistic regression model. For each
bootstrap sample, a full model with all 11 variables in con-
sideration was fit. Then, the variable with the largest
P value (Wald test) was dropped, and a new model was
fit with one fewer variables. This backward elimination
process was repeated until only one variable was retained.
The predictors were then ranked from most significant
(the last one to remain) to least significant (the first one
eliminated). The average rank from 1,000 bootstrap repeti-
tions was used to select the variables for further consider-
ation. Using the best five variables selected in the previous
steps, a multivariable conditional logistic model was fit.
The final model included all variables selected in the previ-
ous steps; no reduction of the model was attempted at this
stage. From each model, we computed the predicted prob-
ability of ARDS for each individual and computed receiver
operating characteristics (ROC) curves and their area
under the curve (AUC). We validated each model using a
bootstrap method (10,000-iteration) and reported the
bootstrap bias-corrected AUCs with 95% bootstrap confi-
dence interval (CI) (15). All analyses were performed with




Patient demographic and clinical characteristics are sum-
marized in Table 1. ARDS cases and sepsis controls were
well matched (by study design) for age, gender, APACHE II
score and number of non-pulmonary organ failures at en-
rollment. Compared to sepsis controls, ARDS cases were
more likely to be Caucasian, had fewer days alive and free
of mechanical ventilation (ventilator-free days) and had
trends towards longer ICU stays and higher hospital mor-
tality (Table 1). Among the ARDS cases, 91 had onset on
ICU day 1 and the remainder had onset on ICU day 2. Se-
verity of ARDS as assessed by the AECC criteria was high,
with the majority (79%) of cases meeting ARDS criteria
(PaO2/FiO2 ≤200) on the day of onset and the minority
(21%) meeting only ALI criteria (200 < PaO2/FiO2 ≤300)
on the day of onset.
Biomarker values
Comparison of biomarker values between cases and
controls is summarized in Table 2. Five biomarkers were
significantly different (P <0.05) in univariable analysis be-
tween cases and controls including SP-D, RAGE, IL-8,CC-16 and IL-6. These five biomarker variables were se-
lected in the model building step and used to construct a
diagnostic model for ALI (Table 3). Model performance
was evaluated by ROC curve analysis. Using the top five
biomarkers (SP-D, RAGE, IL-8, CC-16 and IL-6), the
AUC was 0.75 (95% CI: 0.7 to 0.84) (Table 3, Figure 1)
for the diagnosis of ARDS. By contrast, the AUC for diag-
nosis using single biomarkers was poor with AUCs ran-
ging from 0.59 for IL-6 to 0.69 for SP-D (Table 3). A
nomogram that illustrates the potential clinical use of the
five-biomarker panel is illustrated in Figure 2.
Nine of the patients included as cases had onset of
ARDS after plasma was obtained. To determine if the
biomarker panel performed better if plasma was obtained
when ARDS was already established, we repeated the ana-
lysis excluding the nine cases with onset of ARDS on ICU
day 2 as well as their matched controls. In this analysis, the
model with the top five biomarkers (SP-D, RAGE, IL-8,
CC-16 and IL-6) had an AUC of 0.78 (95% CI: 0.74
to 0.87) (Table 3, Figure 1). As a sensitivity analysis, we
Table 2 Comparison of plasma biomarker levels between 100 severe sepsis patients with ARDS (cases) and 100 severe
sepsis patients without ARDS (controls)
Biomarker Number ARDS cases number = 100 Controls number = 100 P Value
SP-D (ng/ml) 200 86 (46 to 159) 43 (28 to 77) <0.001
RAGE (pg/ml) 200 1,844 (1,060 to 3,737) 1,232 (766 to 2147) <0.001
IL-8 (pg/ml) 200 27.2 (14.2 to 119.5) 16.8 (9.3 to 45.6) 0.006
CC16 (ng/ml) 200 9.2 (5.0 to 15.8) 13.1 (6.3 to 27.8) 0.013
IL-6 (pg/ml) 200 283 (92 to 803) 142 (57 to 550) 0.023
PCPIII (ug/ml) 200 11.5 (6.9 to 18.7) 11.5 (6.7 to 34.2) 0.25
BNP (pg/ml) 200 404 (264 to 748) 412 (212 to 712) 0.38
MMP-9 (ng/ml) 195 151 (67 to 300) 163 (81 to 337) 0.39
MMP-1 (ng/ml) 195 28 (15 to 51) 31 (17 to 56) 0.44
Ang2 (ng/ml) 200 13 (7 to 21) 12 (7 to 20) 0.67
MMP-3 (ng/ml) 195 22 (15 to 35) 22 (14 to43) 0.78
Data as median (interquartile range). ARDS, acute respiratory distress syndrome; SP-D, surfactant protein D; RAGE, receptor for advanced glycation endproducts;
IL-8, interleukin 8; CC16, club cell protein-16; IL-6, interleukin 6; PCPIII, procollagen peptide III; BNP, brain natriuretic peptide; MMP-9, matrix metalloprotease 9;
MMP-1, matrix metalloprotease 1; Ang2, angiopoietin 2; MMP-3, matrix metalloprotease 3.
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(n = 66) who met ARDS criteria on all four days in the
ICU and their matched controls. In this analysis the
model with the top five biomarkers (SP-D, RAGE, IL-8,
CC-16 and IL-6) had an AUC of 0.82 (95% CI: 0.77 to
0.90) (Table 3, Figure 1) compared to single biomarker
performance AUCs ranging from 0.63 (IL-6) to 0.72
(SP-D). We also assessed the sensitivity and specificity
of the diagnostic models. Setting the sensitivity at 70%,
the specificity of the diagnostic model that included all
patients was 68%. Specificity improved to 75% and 83%
when the analysis was restricted to patients with ARDS
on enrollment day or to patients with the ARDS on all
four study days, respectively.
Discussion
The diagnosis of ARDS is based on clinical definitions
that lack both sensitivity and specificity. The goal of the
current study was to test the performance of a panel of
biomarkers for the diagnosis of ARDS and to test if theseTable 3 Comparison of models for diagnosis of ARDS using si
five performing biomarkers
Model All data (100 pa
AUC (95% CI)
Single marker models
SPD 0.69 (0.6, 0.76)
RAGE 0.64 (0.56, 0.72
IL8 0.61 (0.54, 0.69
CC16 0.60 (0.52, 0.68
IL6 0.59 (0.52, 0.67
Multivariable model (includes SPD, RAGE, IL-8, CC16, IL6) 0.75 (0.7, 0.84)
aAll AUCs are bootstrap bias-corrected; all 95% CI are bootstrap CIs. AUC, area unde
respiratory distress syndrome; SP-D, surfactant protein D; RAGE, receptor for advanc
interleukin 6.plasma markers would provide biologic confirmation of
the clinical diagnosis. To reduce clinical heterogeneity, we
focused on patients with severe sepsis, the most common
and most lethal underlying etiology of ARDS [21]. As
hypothesized, a logistic regression model that utilized a
panel of biomarkers had substantially superior perform-
ance to single biomarkers for differentiating sepsis patients
with ARDS from those without ARDS as evaluated by
ROC curve analysis. From among the 11 biomarkers tested
in this exploratory study, a panel that included the five top-
performing biomarkers (SP-D, RAGE, IL-8, CC-16 and
IL-6) had an AUC of 0.75 (95% CI: 0.7 to 0.84) for the
diagnosis of ARDS. Performance of the biomarker panel
was further enhanced when only patients with ARDS at
the time of blood draw (AUC 0.78) or patients with the
most severe ARDS (AUC 0.82) were considered.
The best performing biomarkers for the diagnosis of
ARDS in the current study of patients with severe sepsis
were different from the best performing biomarkers identi-
fied in a similar study in patients with severe trauma [6],ngle biomarkers to a combined model utilizing the top
irs) Enrollment day cases (91 pairs) Severe cases only (66 pairs)
a AUC (95% CI)a AUC (95% CI)a
0.71 (0.63, 0.79) 0.72 (0.62, 0.81)
) 0.68 (0.6, 0.75) 0.67 (0.57, 0.76)
) 0.63 (0.55, 0.7) 0.64 (0.55, 0.73)
) 0.60 (0.52, 0.68) 0.64 (0.55, 0.74)
) 0.61 (0.53, 0.69) 0.63 (0.53, 0.72)
0.78 (0.74, 0.87) 0.82 (0.77, 0.9)
r the receiver operator characteristic curve; CI, confidence interval; ARDS, acute
ed glycation endproducts; IL-8, interleukin 8; CC16, club cell protein-16; IL-6,



















Figure 1 Receiver operator characteristic (ROC) curve analysis
of the plasma biomarker panels for differentiating ARDS (cases)
from controls. Predicted probability of ARDS for each subject was
computed from a logistic regression model that includes the top
five biomarkers (SP-D, RAGE, IL-8, CC-16 and IL-6). Specificity and
sensitivity were computed at each possible cutoff of the predicted
probability. Three ROC analyses are shown. The solid line shows
the ROC analysis for all 200 patients in the study (100 cases, 100
controls). The AUC is 0.75 (95% CI: 0.7 to 0.84). The dashed line
shows the ROC analysis using only the 91 cases who had ARDS at
the time of the blood draw for biomarker measurement as well as
their matched controls. The AUC for this model is 0.78 (95% CI:
0.74 to 0.87). The dotted line shows the ROC analysis using only
the 66 patients who had the most severe ARDS (ARDS on all study
days) and their matched controls. The AUC for this model is 0.82
(95% CI: 0.77 to 0.90). ROC, receiver operator characteristic curve;
ARDS, acute respiratory distress syndrome; SP-D, surfactant protein
D; RAGE, receptor for advanced glycation endproducts; IL-8, inter-
leukin 8; CC16, club cell protein-16; IL-6, interleukin 6; AUC, area
under the receiver operator characteristic curve; CI, confidence
interval.
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best performing biomarkers were RAGE, PCPIII, BNP,
ANG2, IL10, TNF-α, and IL8 with an AUC of 0.86 for
differentiating patients with ARDS from critically ill
trauma patients without ARDS. Two biomarkers, RAGE
and IL-8, contributed to diagnostic models in both studies.
In trauma patients, biomarkers of fibroblast activation
(PCPIII), endothelial injury (ANG2), other inflammatory
markers (IL-10, TNF) and heart failure (BNP, lower in
ARDS) were also useful for differentiating cases from con-
trols whereas in sepsis, biomarkers of lung epithelial injury
(SPD, RAGE, CC16) and inflammation (IL6, IL8) predom-
inate. These differences may reflect important differences
in the pathophysiology of both the underlying conditions
(trauma and sepsis) as well as differences in the patho-
physiology of ARDS in these different clinical settings.Three of the top five performing biomarkers in the
current study were biomarkers of lung epithelial injury.
SP-D is a normal constituent of surfactant that is pro-
duced almost exclusively by the alveolar epithelial type II
cell. Elevated levels of SP-D have been reported in the
circulation in patients with ARDS compared to those
with hydrostatic pulmonary edema [22] and higher levels
have been independently associated with 180-day mortal-
ity and reduced ventilator and organ-failure free days in
patients with ARDS [23]. RAGE, although ubiquitously
expressed, is most highly expressed by the type I alveolar
cell [24]. Similar to SP-D, higher plasma levels of RAGE
have been associated with adverse outcomes in patients
with ARDS [25]. CC16 is a small 16 kDa protein secreted
by the club cells of the distal airway (previously known as
Clara cells). In contrast to other lung epithelial markers,
lower levels of CC16 have previously been associated with
ARDS [26] although one small study reported an increase
in levels at the time of onset of ARDS in patients with
ventilator-associated pneumonia [27]. In the current study,
lower levels of CC16 were associated with the diagnosis of
ARDS. Taken together with prior studies of lung epithelial
markers and prognosis of ARDS, the current findings indi-
cate that alterations in the plasma levels of biomarkers of
lung epithelial injury are key features that can be used to
differentiate both the presence and the severity of ARDS
in patients with sepsis. Measures of lung epithelial injury
might be particularly useful in selecting patients likely to
benefit from lung-epithelial targeted therapies such as
keratinocyte growth factor [28-30] in future clinical trials
in ARDS.
This study has both strengths and limitations. Major
strengths include the detailed, daily prospective patient
phenotyping for ARDS as part of the VALID cohort study,
and the matching of cases and controls for important clin-
ical characteristics, such as age, gender, severity of illness
and number of non-pulmonary organ failures. This strin-
gent matching of cases and controls eliminates severity of
illness as the primary determinant of differences in bio-
marker levels in this exploratory study, thus making it
more likely that biomarkers that truly reflect the presence
of ARDS have been identified. Limitations of the study in-
clude the retrospective single center design and the case
control study design. A case control design is more likely
to overestimate the association between a given biomarker
and the diagnosis of ARDS compared to a prospective co-
hort design. In addition, the study included only 11 bio-
markers and thus was not an exhaustive examination of
all potential biomarkers that might be useful for the diag-
nosis of ARDS. Nevertheless, the simultaneous compari-
son of performance of 11 biomarkers for the diagnosis of
ARDS in patients with severe sepsis provides important
new information about the relative performance of a var-
iety of plasma biomarkers of different aspects of the
Points
0 10 20 30 40 50 60 70 80 90 100
SPD
8 16 34 57 117 304 572
RAGE
300 500 900 2800 7800
IL8
2 5 23 1084 9600
CC16
146 69 22 11 6 3 1
IL6
7 16 77 220 707 9033 39719
Total Points
0 20 40 60 80 100 120 140 160 180 200 220 240
Probability of ARDS
0.1 0.2 0.4 0.6 0.8 0.9
Figure 2 The multivariable logistic regression model was used to create a prediction model nomogram for the probability of ARDS. A value
in each biomarker predictor variable corresponds to a point scale at the top. The sum of the individual predictor variable points corresponds to the total
points and the probability of ARDS shown at the bottom. For each predictor variable, the shown values are approximately 1st, 5th, 25th, 50th, 75th, 95th,
and 99th percentiles. ARDS, acute respiratory distress syndrome.
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ously been available from the many single biomarker stud-
ies in ARDS.
Conclusions
In conclusion, abnormal levels of five biomarkers in
plasma provided excellent discrimination for the diagnosis
of ARDS in patients with severe sepsis as assessed by
ROC curve analysis. Three of the five biomarkers were
generated by the lung epithelium, suggesting that lung
epithelial injury is a critical determinant of alveolar flood-
ing and the subsequent arterial hypoxemia and bilateral
opacities that constitute the clinical definition of ARDS, a
finding that is concordant with evidence that impaired al-
veolar epithelial fluid clearance is characteristic of patients
with ARDS [31,32]. Although the definition of ARDS
is based on clinical criteria, altered levels of plasma bio-
markers may be useful to assist in confirming the diagno-
sis in patients with shock and possible sepsis, and also
potentially selecting patients for clinical trials that are de-
signed to reduce lung epithelial injury [5,28]. The bio-
marker panel might also be useful to categorize patients
with sepsis-induced ARDS by their biologic profile as well
as their clinical profile, as has been done recently in other
lung disease, such as asthma [33].
Key messages
 Among a panel of 11 biomarkers of various aspects
of the pathophysiology of ARDS, biomarkers of lung
epithelial injury and inflammation were the most
useful for discriminating sepsis patients with ARDS
from those without ARDS.
 A five biomarker panel that included SP-D, RAGE,
CC-16, IL-8 and IL-6 had an area under the ROCcurve of 0.75 (95% CI: 0.7 to 0.84) for diagnosis of
ARDS.
 For diagnosis of more severe ARDS the area under
the ROC curve was 0.82 (95% CI: 0.77 to 0.90).
 Altered levels of plasma biomarkers may be useful
biologic confirmation of the diagnosis of ARDS in
patients with sepsis.
 A biomarker panel that includes biomarkers of lung
epithelial injury and inflammation may be useful for
selecting patients for clinical trials that are designed
to reduce lung epithelial injury.
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